Castleman disease
Castleman disease
Explore linked clinical trials. Standard reference: MONDO:00155649 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease | AIDS, Blood-Borne Infections, Castleman disease, DNA Virus Infections, Genital Diseases, HIV infectious disease, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Kaposi's sarcoma, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, RNA Virus Infections, Slow Virus Diseases, Urogenital Diseases, immune system disorder, immunoproliferative disorder, inborn error of immunity, infectious disease, lentivirus infection, lymphatic system disorder, lymphoproliferative syndrome, neoplasm, sarcoma, sexually transmitted disease, uterine carcinosarcoma, vascular cancer, viral infectious disease, viral sexually transmitted disease | Recruiting | Not stated | 2026-09-28 | NCT03300830 | |
| A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH | Abnormalities, Multiple, Blood Protein Disorders, Castleman disease, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, POEMS syndrome, Skin and Connective Tissue Diseases, amyloidosis, cardiovascular disorder, cryoglobulinemia, heavy chain deposition disease, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, light chain deposition disease, lymphatic system disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, monoclonal gammopathy of uncertain significance, neoplasm, nervous system disorder, neuromuscular disease, peripheral nervous system disorder, plasma cell leukemia, plasma cell neoplasm, polyneuropathy, precancerous condition, proteostasis deficiencies, skin disorder, skin vascular disease, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic disease | Recruiting | Not stated | 2026-09-16 | NCT05283993 | |
| Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease | Castleman disease, Hemic and Lymphatic Diseases, Multi-centric Castleman's Disease, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoproliferative syndrome, macular corneal dystrophy | Active, not recruiting | Phase 2 | 2026-08-20 | NCT03933904 | |
| Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease | Castleman disease, Hemic and Lymphatic Diseases, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoproliferative syndrome | Recruiting | Phase 2 | 2026-04-22 | NCT07085039 | |
| International Registry for Patients With Castleman Disease | Castleman disease, Hemic and Lymphatic Diseases, Multi-centric Castleman's Disease, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoproliferative syndrome, macular corneal dystrophy | Recruiting | Not stated | 2026-03-03 | NCT02817997 | |
| Registry for Adults With Plasma Cell Disorders (PCD's) | Abnormalities, Multiple, Blood Protein Disorders, Castleman disease, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, POEMS syndrome, Skin and Connective Tissue Diseases, amyloidosis, cardiovascular disorder, cryoglobulinemia, heavy chain deposition disease, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, light chain deposition disease, lymphatic system disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, nervous system disorder, neuromuscular disease, peripheral nervous system disorder, plasma cell leukemia, plasma cell neoplasm, polyneuropathy, precancerous condition, proteostasis deficiencies, skin disorder, skin vascular disease, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic disease | Recruiting | Not stated | 2025-11-20 | NCT03717844 | |
| AutoInflammatory Disease Alliance Registry (AIDA) | Behcet disease, Castleman disease, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, Marshall syndrome, PFAPA syndrome, Schnitzler syndrome, Skin and Connective Tissue Diseases, Spondylarthritis, Stomatognathic Diseases, VEXAS syndrome, anterior uveitis, arthritic joint disease, arthropathy, autoimmune disease, bone disorder, cardiovascular disorder, connective tissue disorder, eye disorder, hereditary disease, hereditary periodic fever syndrome, hereditary skin disorder, immune system disorder, immunoproliferative disorder, juvenile idiopathic arthritis, lymphatic system disorder, lymphoproliferative syndrome, monoclonal gammopathy, monoclonal gammopathy of uncertain significance, mouth disorder, musculoskeletal system disorder, panuveitis, rheumatic disorder, scleral disorder, scleritis, skin disorder, skin vascular disease, spondylitis, systemic-onset juvenile idiopathic arthritis, uveal disorder, uveitis, vascular disorder, vasculitis, vertebral column disorder | Recruiting | Not stated | 2025-07-10 | NCT05200715 | |
| An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context | Castleman disease, Hemic and Lymphatic Diseases, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoproliferative syndrome | Recruiting | Not stated | 2024-12-06 | NCT06720870 | |
| Nintedanib Treatment in Unicentric Castleman Disease | Castleman disease, Hemic and Lymphatic Diseases, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoproliferative syndrome | Not yet recruiting | Phase 2 | 2024-10-15 | NCT06643091 |